~~<i id='708F468309'><strike id='708F468309'><tt id='708F468309'><pre id='708F468309'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：explore 2025-09-28 12:39:13 Page View：965

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Carvykti CAR
Next article： Cancer drug shortages should be causing more outrage

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

HCA sued by state AG for quality issues at Mission Health

MissionhealthsysteminNorthCarolina.MikeBellemeforSTATNorthCarolina’sattorneygeneralissuingHCAHealthc

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

DarronCummings/APAcouplebillionhere,acouplebillionthere,andprettysoonEliLillyhopesitwillbetalkingabo

WSS

hotspot

hotspot

leisure time

explore

Eli Lilly buys Point Biopharma in radiopharmaceuticals play